

# Georg Hansmann

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7520375/georg-hansmann-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200  
papers

9,257  
citations

31  
h-index

96  
g-index

229  
ext. papers

11,646  
ext. citations

5.1  
avg, IF

6.02  
L-index

#	Paper	IF	Citations
200	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for	9.5	3455
199	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung	13.6	1672
198	Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. <i>Circulation</i> , <b>2015</b> , 132, 2037-99	16.7	624
197	Patent ductus arteriosus of the preterm infant. <i>Pediatrics</i> , <b>2010</b> , 125, 1020-30	7.4	328
196	Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. <i>Circulation</i> , <b>2007</b> , 115, 1275-84	16.7	312
195	An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 1846-57	15.9	285
194	Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2012</b> , 2, 170-81	2.7	158
193	2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2016</b> , 69, 177	0.7	148
192	2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 879-901	5.8	133
191	PPAR $\alpha$ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	113
190	PPAR $\alpha$ links BMP2 and TGF $\beta$ Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism. <i>Cell Metabolism</i> , <b>2017</b> , 25, 1118-1134.e7	24.6	97
189	Therapeutic hypothermia in neonates. Review of current clinical data, ILCOR recommendations and suggestions for implementation in neonatal intensive care units. <i>Resuscitation</i> , <b>2008</b> , 78, 7-12	4	83
188	Pulmonary Hypertension in Infants, Children, and Young Adults. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2551-2569	15.1	78
187	The Sugén 5416/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up. <i>Pulmonary Circulation</i> , <b>2014</b> , 4, 619-29	2.7	77
186	Engineered alginate hydrogels for effective microfluidic capture and release of endothelial progenitor cells from whole blood. <i>Langmuir</i> , <b>2011</b> , 27, 4257-64	4	67
185	Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102 Suppl 2, ii86-100	5.1	67
184	PPAR $\gamma$ activation: a potential treatment for pulmonary hypertension. <i>Science Translational Medicine</i> , <b>2009</b> , 1, 12ps14	17.5	60

183	Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. <i>Heart</i> , <b>2016</b> , 102, 390-6	5.1	59
182	Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102 Suppl 2, ii102-8	5.1	54
181	Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102 Suppl 2, ii49-56	5.1	52
180	Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102 Suppl 2, ii109-16	5.1	50
179	Normal Reference Values and z Scores of the Pulmonary Artery Acceleration Time in Children and Its Importance for the Assessment of Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , <b>2017</b> , 10,	3.9	48
178	Transthoracic echocardiography in the evaluation of pediatric pulmonary hypertension and ventricular dysfunction. <i>Pulmonary Circulation</i> , <b>2016</b> , 6, 15-29	2.7	44
177	Inhibition of hypoxia-induced apoptosis by modulation of retinoblastoma protein-dependent signaling in cardiomyocytes. <i>Circulation Research</i> , <b>2002</b> , 91, 782-9	15.7	43
176	Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102 Suppl 2, ii67-85	5.1	43
175	Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102 Suppl 2, ii42-8	5.1	43
174	Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102 Suppl 2, ii1-13	5.1	38
173	Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102 Suppl 2, ii57-66	5.1	38
172	Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension. <i>Journal of Molecular Medicine</i> , <b>2011</b> , 89, 971-83	5.5	36
171	Thrombocytopenia in the first 24 hours after birth and incidence of patent ductus arteriosus. <i>Pediatrics</i> , <b>2012</b> , 130, e623-30	7.4	36
170	Natural History of Patent Ductus Arteriosus in Very Low Birth Weight Infants after Discharge. <i>Journal of Pediatrics</i> , <b>2015</b> , 167, 1149-51	3.6	30
169	Patent Ductus Arteriosus of the Preterm Infant. <i>Pediatrics</i> , <b>2020</b> , 146,	7.4	30
168	Recent Advances in the Treatment of Preterm Newborn Infants with Patent Ductus Arteriosus. <i>Clinics in Perinatology</i> , <b>2016</b> , 43, 113-29	2.8	29
167	Characterization by antagonists of P2-receptors mediating endothelium-dependent relaxation in the rat aorta. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1997</b> , 356, 641-52	3.4	29
166	Pulmonary hypertension in bronchopulmonary dysplasia. <i>Pediatric Research</i> , <b>2021</b> , 89, 446-455	3.2	29

165	LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPAR $\alpha$ Activation. <i>Circulation Research</i> , <b>2019</b> , 124, 1778-1785	15.7	28
164	Hypothermia: an evolving treatment for neonatal hypoxic ischemic encephalopathy. <i>Pediatrics</i> , <b>2008</b> , 121, 648-9; author reply 649-50	7.4	28
163	Cardiac MR and CT imaging in children with suspected or confirmed pulmonary hypertension/pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102 Suppl 2, ii30-5	5.1	27
162	First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893217743123	2.7	25
161	First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 551-554	2.7	24
160	The PPAR $\delta$ agonist pioglitazone prevents TGF- $\beta$ -induced renal fibrosis by repressing EGR-1 and STAT3. <i>BMC Nephrology</i> , <b>2019</b> , 20, 245	2.7	23
159	Neonatal resuscitation on air: it is time to turn down the oxygen tanks [corrected]. <i>Lancet, The</i> , <b>2004</b> , 364, 1293-4	4.0	23
158	PPAR $\delta$ is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2020</b> , 29, 171-179	3.5	22
157	Red blood cell-derived semaphorin 7A promotes thrombo-inflammation in myocardial ischemia-reperfusion injury through platelet GPIb. <i>Nature Communications</i> , <b>2020</b> , 11, 1315	17.4	21
156	Sympathetic nervous system controls resolution of inflammation via regulation of repulsive guidance molecule A. <i>Nature Communications</i> , <b>2019</b> , 10, 633	17.4	20
155	Hypoxia drives cardiac miRNAs and inflammation in the right and left ventricle. <i>Journal of Molecular Medicine</i> , <b>2019</b> , 97, 1427-1438	5.5	17
154	Inhibition of neogenin fosters resolution of inflammation and tissue regeneration. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 4711-4726	15.9	17
153	Activation of the Metabolic Master Regulator PPAR $\alpha$ A Potential Pioneering Therapy for Pulmonary Arterial Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2020</b> , 62, 143-156	5.7	16
152	Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , <b>2018</b> , 272S, 4-10	3.2	16
151	Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 695-706	5.8	15
150	Echocardiographic Reference Values for Right Atrial Size in Children with and without Atrial Septal Defects or Pulmonary Hypertension. <i>Pediatric Cardiology</i> , <b>2016</b> , 37, 686-95	2.1	15
149	Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2020</b> , 10, 1580-1603	2.6	15
148	Tricuspid annular plane systolic excursion (TAPSE) in pediatric pulmonary hypertension: Integrating right ventricular ejection efficiency (RVEe) into advanced multi-parametric imaging. <i>International Journal of Cardiology</i> , <b>2019</b> , 274, 296-298	3.2	14

147	Non-Invasive Imaging for Congenital Heart Disease: Recent Innovations in Transthoracic Echocardiography. <i>Journal of Clinical &amp; Experimental Cardiology</i> , <b>2012</b> , Suppl 8, 2	0	14
146	Ductal closure in neonates: a developmental perspective on platelet-endothelial interactions. <i>Blood Coagulation and Fibrinolysis</i> , <b>2011</b> , 22, 242-4	1	13
145	Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2463-2477	15.1	12
144	Transforming Growth Factor $\beta$ - and Bone Morphogenetic Protein 2/PPAR $\beta$ -regulated MicroRNAs in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 1227-1228	10.2	12
143	Trans-Right-Ventricle and Transpulmonary MicroRNA Gradients in Human Pulmonary Arterial Hypertension. <i>Pediatric Critical Care Medicine</i> , <b>2020</b> , 21, 340-349	3	12
142	Genetic testing and blood biomarkers in paediatric pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , <b>2016</b> , 102, 1021-1024	5.1	12
141	Right ventricular outflow tract velocity time integral (RVOT VTI) and tricuspid regurgitation velocity/RVOT VTI ratio in pediatric pulmonary hypertension. <i>International Journal of Cardiology</i> , <b>2016</b> , 212, 274-6	3.2	12
140	Nucleotide-evoked relaxation of human coronary artery. <i>European Journal of Pharmacology</i> , <b>1998</b> , 359, 59-67	5.3	11
139	Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension. <i>Heart</i> , <b>2020</b> , 106, 1332-1341	5.1	10
138	Association between Platelet Counts before and during Pharmacological Therapy for Patent Ductus Arteriosus and Treatment Failure in Preterm Infants. <i>Frontiers in Pediatrics</i> , <b>2018</b> , 6, 41	3.4	10
137	Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2020</b> , 10, 1675-1685	2.6	10
136	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	8
135	Chronic TGF- $\beta$ Signaling in Pulmonary Arterial Hypertension Induces Sustained Canonical Smad3 Pathways in Vascular Smooth Muscle Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2019</b> , 61, 121-123	5.7	8
134	Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018793580	2.7	8
133	Emphysema Is-at the Most-Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1447-1450	10.2	7
132	Diagnostics in Children and Adolescents with Suspected or Confirmed Pulmonary Hypertension. <i>Paediatric Respiratory Reviews</i> , <b>2017</b> , 23, 3-15	4.8	7
131	Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologists. <i>Pulmonary Circulation</i> , <b>2013</b> , 3, 792-801	2.7	7
130	Systematic underestimation of oxygen delivery in ventilated preterm infants. <i>Neonatology</i> , <b>2010</b> , 98, 18-22	4	7

129	Mature and immature platelets during the first week after birth and incidence of patent ductus arteriosus. <i>Cardiology in the Young</i> , <b>2020</b> , 30, 769-773	1	6
128	Right ventricular base/apex ratio in the assessment of pediatric pulmonary arterial hypertension: Results from the European Pediatric Pulmonary Vascular Disease Network. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 1144-1149	3.3	6
127	Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2020</b> , 10, 1659-1674	2.6	6
126	Right ventricular end-systolic remodeling index in the assessment of pediatric pulmonary arterial hypertension. The European Pediatric Pulmonary Vascular Disease Network (EPPVDN). <i>Pediatric Research</i> , <b>2020</b> , 88, 285-292	3.2	5
125	The Need for Comprehensive Cardiac Catheterization in Children With Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1009-1010	15.1	5
124	Ventricular-ventricular interaction variables correlate with surrogate variables of clinical outcome in children with pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2019</b> , 9, 2045894019854074	2.7	5
123	Vasoconstrictor and vasodilator effects of guanine nucleotides in the rat aorta. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1997</b> , 356, 653-61	3.4	5
122	Repurposing of medications for pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020941494	2.7	5
121	Emerging therapies for right ventricular dysfunction and failure. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2020</b> , 10, 1735-1767	2.6	5
120	Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2020</b> , 10, 1522-1540	2.6	5
119	RNA expression profiles and regulatory networks in human right ventricular hypertrophy due to high pressure load. <i>iScience</i> , <b>2021</b> , 24, 102232	6.1	5
118	Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. <i>Cardiology in the Young</i> , <b>2019</b> , 29, 1323-1327	1	4
117	The Adult Sprague-Dawley Sugen-Hypoxia Rat Is Still "the One:" A Model of Group 1 Pulmonary Hypertension: Reply to Le Cras and Abman. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 621-624	10.2	4
116	Animal models of right heart failure. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2020</b> , 10, 1561-1579	2.6	4
115	Recommendations from the Association for European Paediatric and Congenital Cardiology for clinical training in paediatric heart failure and transplantation. <i>Cardiology in the Young</i> , <b>2018</b> , 28, 1295-1298	1	4
114	Platelet-rich plasma for the treatment of patent ductus arteriosus: not quite ready for prime time. <i>Cardiology in the Young</i> , <b>2015</b> , 25, 139-40	1	3
113	The right ventricular outflow tract in pediatric pulmonary hypertension-Data from the European Pediatric Pulmonary Vascular Disease Network. <i>Echocardiography</i> , <b>2018</b> , 35, 841-848	1.5	3
112	Besondere Notfallsituationen bei Frñ- und Reifgeborenen. <i>Monatsschrift Fur Kinderheilkunde</i> , <b>2008</b> , 156, 489-504	0.2	3

111	Diagnosis and treatment of right ventricular dysfunction in congenital heart disease. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2020</b> , 10, 1625-1645	2.6	3
110	The first Keystone Symposia Conference on pulmonary vascular disease and right ventricular dysfunction: Current concepts and future therapies. <i>Pulmonary Circulation</i> , <b>2013</b> , 3, 275-7	2.7	2
109	Mineralocorticoid receptor blockade improves pulmonary hypertension and right ventricular function in bronchopulmonary dysplasia: a case report. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2020</b> , 10, 1686-1690	2.6	2
108	Dringende Notwendigkeit des Off-label-Einsatzes von PAH-Medikamenten und deren Erstattung bei Kindern mit pulmonaler Hypertonie (Lungenhochdruck). <i>Monatsschrift Fur Kinderheilkunde</i> , <b>2020</b> , 168, 733-738	0.2	1
107	Echocardiographic estimation of elevated right ventricular afterload in preterm infants at risk for pulmonary hypertension: next steps. <i>Journal of Pediatrics</i> , <b>2018</b> , 202, 335-336	3.6	1
106	Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension. <i>Pediatric Cardiology</i> , <b>2017</b> , 38, 1523-1524	2.1	1
105	Cleft palate460-463		1
104	Endotracheal intubation and gastric tube placement82-95		1
103	Neonatal emergency call: what the neonatology team would like to know from obstetricians and midwives9-10		1
102	Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young. <i>Diagnostics</i> , <b>2020</b> , 11,	3.8	1
101	A novel echocardiographic approach indicates disease severity in pediatric pulmonary hypertension. <i>Pediatrics International</i> , <b>2020</b> , 62, 637-639	1.2	1
100	Current Controversy on Platelets and Patent Ductus Arteriosus Closure in Preterm Infants. <i>Frontiers in Pediatrics</i> , <b>2021</b> , 9, 612242	3.4	1
99	Toward a standardized multidisciplinary team approach in preterm infants at-risk for pulmonary hypertension. <i>Journal of Perinatology</i> , <b>2021</b> , 41, 801-802	3.1	1
98	Soluble Receptor for Advanced Glycation End Products (sRAGE) Is a Sensitive Biomarker in Human Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
97	Pulmonary Arterial Hypertension and Consecutive Right Heart Failure Lead to Liver Fibrosis.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 862330	5.4	1
96	Extremely premature infants born at 23-25 weeks gestation are at substantial risk for pulmonary hypertension.. <i>Journal of Perinatology</i> , <b>2022</b> ,	3.1	1
95	Diagnosis and management of pulmonary hypertension in infants with bronchopulmonary dysplasia. <i>Seminars in Fetal and Neonatal Medicine</i> , <b>2022</b> , 101351	3.7	1
94	Birth trauma: brachial plexus palsy, facial nerve palsy, clavicular fracture, skull fracture, intracranial and subperiosteal hemorrhage (cephalohematoma)464-467		0

93	Interventional creation of an endogenous reverse Potts shunt in an infant with pulmonary hypertension and genetic surfactant disorder-a case report. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2020</b> , 10, 1696-1700	2.6	o
92	Off-label use of PAH-targeted medications approved for adults and their financial coverage by health insurances are vital for children with pulmonary hypertension. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13571	4.6	o
91	Generation of pulmonary arterial hypertension patient-specific induced pluripotent stem cell lines from three unrelated patients with a heterozygous missense mutation in exon 12, a heterozygous in-frame deletion in exon 3 and a missense mutation in exon 11 of the BMPR2 gene. <i>Stem Cell Research</i> , <b>2021</b> , 55, 102488	1.6	o
90	Interplay of Low-Density Lipoprotein Receptors, LRP6, and Lipoproteins in Pulmonary Hypertension.. <i>JACC Basic To Translational Science</i> , <b>2022</b> , 7, 164-180	8.7	o
89	Letter by Legchenko et al Regarding Article, "Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to-Mesenchymal Transition in Human Right Ventricular Failure".. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008503	7.6	o
88	Circulating Endothelial Cell Quantification by Microfluidics Chip in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2017</b> , 56, 680-682	5.7	
87	A pediatric perspective on the TAPSE/PASP ratio in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , <b>2019</b> , 278, 242	3.2	
86	Reply to "Diagnostic and prognostic value of echocardiography in pulmonary arterial hypertension". <i>Clinical Cardiology</i> , <b>2018</b> , 41, 1152-1153	3.3	
85	Different indications for transcatheter and surgical patent ductus arteriosus closure in preterm infants less than 2kg. <i>International Journal of Cardiology</i> , <b>2018</b> , 266, 83	3.2	
84	Hemolytic disease of the newborn423-426		
83	Hydrops fetalis427-431		
82	Choanal atresia432-433		
81	Gastrointestinal obstruction437-446		
80	Necrotizing enterocolitis (NEC)447-449		
79	Omphalocele and gastroschisis450-454		
78	Neural tube defects455-459		
77	Sudden infant death syndrome (SIDS)468-471		
76	Questions for review472-476		



- 75 Transport of preterm and term infants493-503
- 74 Acute antenatal transfer504-505
- 73 Questions for review506-506
- 72 Training NICU nurses and paramedics in the neonatal emergency transport service (NETS)509-510
- 71 Training delivery room staff in the resuscitation of newborn infants511-512
- 70 Web links: societies, hospitals, guidelines and learning programs513-514
- 69 Growth charts515-515
- 68 Bilirubin diagrams and transfusion exchange limits516-516
- 67 Aortic blood pressure during the first 12h of life in infants with birth weight 610-220 g517-517
- 66 Laboratory: normal values518-524
- 65 Unit conversions525-525
- 64 An apparently trivial call from the term baby nursery243-248
- 63 Meconium aspiration269-279
- 62 Chorioamnionitis and early-onset sepsis in the newborn infant280-303
- 61 Twin-twin (feto-fetal) transfusion syndrome240-242
- 60 Out of hospital birth249-259
- 59 Perinatal hemorrhage304-309
- 58 Cerebral seizures317-321

- 57 Infants born to mothers on psychoactive substances322-324
- 56 Prenatal and postnatal arrhythmias325-339
- 55 Critical congenital cardiovascular defects340-379
- 54 Congenital cystic adenomatoid malformation of the lung (CAM, CCAM)417-418
- 53 Chylothorax419-422
- 52 Perinatal hypoxia-ischemia310-316
- 51 Hygiene in the delivery room and during neonatal transport (infection control)133-133
- 50 When to call a pediatrician to the delivery room134-135
- 49 Assigning individual duties in the delivery room140-141
- 48 Checklist for the postnatal treatment of newborn infants136-139
- 47 Cardiopulmonary resuscitation of newborn infants at birth150-172
- 46 Volume therapy and sodium bicarbonate supplementation in preterm and term newborn infants173-178
- 45 Mechanical ventilation of the neonate193-209
- 44 Questions for review (basics)210-211
- 43 Clinical assessment of the newborn infant142-149
- 42 Absolute and relative indications for neonatal transport and NICU admission179-180
- 41 Communication with mother and father181-181
- 40 Coordinating neonatal transport and patient sign-out to the NICU team182-182

- 39 Documentation and feedback after neonatal emergency transport 183-183
- 38 Ethics in neonatal intensive care 184-190
- 37 Perinatal images of preterm and term infants 191-192
- 36 Management of healthy, term newborn infants (vaginal delivery, cesarean section, vacuum extraction, forceps delivery) 221-226
- 35 Management of preterm and moderately depressed term newborn infants with a birth weight  $\geq 500$  g 227-230
- 34 Management of very preterm newborn infants (VLBW, ELBW) 231-239
- 33 Interdisciplinary approach for neonatal emergencies 5-8
- 32 Coordinating health care providers after a neonatal emergency call 11-12
- 31 What the neonatologist would like to find in the delivery room 13-14
- 30 What the neonatologist does not want to find in the delivery room 15-15
- 29 Definitions and abbreviations in neonatology, pediatric cardiology, neonatal emergency transport service (NETS), and obstetrics 16-23
- 28 Basic equipment setup for initial neonatal care and resuscitation 25-40
- 27 Drugs for neonatal emergencies 41-62
- 26 Suctioning 67-70
- 25 Stimulation, oxygen supplementation, bag-and-mask ventilation (M-PPV), pharyngeal/bi-nasal CPAP, and pharyngeal positive pressure ventilation 71-81
- 24 Chest compressions 101-104
- 23 Peripheral venous access 105-106
- 22 Umbilical vein/artery catheterization (UVC, UAC) 107-111

21 Postnatal cardiopulmonary adaptation 63-66

20 Central venous access (internal jugular vein) 112-116

19 Intraosseous access 117-120

18 Cord clamping 121-123

17 Management of high-risk infants in the delivery room 124-130

16 Monitoring in the delivery room and during neonatal transport 131-132

15 History and challenges of neonatal emergency transport services (NETS) 1-4

14 Esophageal atresia 434-436

13 Persistent pulmonary hypertension of the newborn (PPHN) 392-403

12 Patent ductus arteriosus of the preterm infant 380-391

11 Laryngeal mask airway (LMA) 96-100

10 References (Section 1) 24-24

9 References (Section 2) 212-220

8 References (Section 4) 507-508

7 References (Section 5) 526-526

6 References (Section 3) 477-492

5 Circulating Interleukin-7 in Human Pulmonary Arterial Hypertension.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 794549 5-4

4 Getting to the bottom of right heart failure. *Cardiovascular Diagnosis and Therapy*, **2020**, 10, 1517-1521 2.6

- 3 Paediatric/congenital cardiology physician scientists-An endangered species. *European Journal of Clinical Investigation*, **2020**, 50, e13367 4.6
- 2 Subcostal Echocardiographic Imaging in Neonatal and Pediatric Intensive Care. *Frontiers in Pediatrics*, **2021**, 9, 471558 3.4
- 1 Construction of transcriptional regulatory networks using total RNA-seq data. *STAR Protocols*, **2021**, 2, 100769 1.4